The protein granulocyte-colony stimulating factor (G-CSF) inhibited fibrosis in a mouse model of pulmonary fibrosis, a new study…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A new molecular probe could aid in studies of pulmonary fibrosis and other fibrotic diseases, a study reports. The…
The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, has launched a competition…
New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe…
Severe fatigue is common among people with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis, and is associated with…
Across the world, a fair amount of variation exists in medical practices to diagnose and treat acute exacerbations of…
Abnormal buildup of iron in the lungs can cause lung fibrosis (scarring), and targeting this accumulation could be a therapeutic…
COVID-19 has been reported to cause lung fibrosis in some people, but the type of fibrosis that develops is distinct…
Engineered models of the lung and trachea replicate the cellular dynamics found in living organisms better than other models used…
Ofev (nintedanib) limits the decline in lung function in people with idiopathic pulmonary fibrosis (IPF), regardless of the…